CLINICAL TRIALS PROFILE FOR BRIVIACT
✉ Email this page to a colleague
All Clinical Trials for BRIVIACT
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00160667 ↗ | A Study Assessing Efficacy of Brivaracetam in Subjects With Persistent Pain After Shingles (Post-herpetic Neuralgia) | Completed | UCB Pharma | Phase 2 | 2004-10-11 | Study will assess efficacy, safety and tolerability of brivaracetam in post-herpetic neuralgia (PHN). Duration of 7 weeks divided into 3 periods with no up-titration, nor down-titration. |
NCT00175825 ↗ | A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures. | Completed | UCB Pharma | Phase 2 | 2005-11-07 | This trial will evaluate the efficacy and safety of brivaracetam (at doses of 5, 20 and 50 mg/day in twice a day administration) as add-on therapy in subjects with focal epilepsy. |
NCT03021018 ↗ | A Study to Assess the Efficacy and Safety of Brivaracetam as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting | Completed | UCB Biopharma S.P.R.L. | Phase 2 | 2017-02-06 | The purpose of this study is to assess the efficacy of intravenous brivaracetam (BRV) compared to intravenous lorazepam (LZP) in subjects with epilepsy undergoing Epilepsy Monitoring Unit (EMU) evaluation who experience seizures that require prompt treatment. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for BRIVIACT
Condition Name
Clinical Trial Locations for BRIVIACT
Trials by Country
Clinical Trial Progress for BRIVIACT
Clinical Trial Phase
Clinical Trial Sponsors for BRIVIACT
Sponsor Name